A decision-ready blueprint
A business development and partnering solution designed around the commercial realities of cell & gene therapy developers.
Scientific, commercial, and digital architecture, with specialist expertise assembled where the engagement requires it.
Cell and gene therapy developers need a clear route from scientific evidence and development progress to the partner, licensing, financing, or portfolio decision that comes next. Effective business development depends on evidence that can be assessed quickly without losing its scientific, commercial, or regulatory context.
Lonrú Consulting designs the operating architecture around that work. We connect the approved evidence, market intelligence, decision criteria, and review ownership needed to prepare a credible partner narrative and manage the opportunities that follow.
We define the scientific, clinical, CMC, commercial, market, and partner information relevant to the selected transaction or business-development question, including permissions and evidence boundaries.
Configured systems can structure approved material, prepare comparative analysis, surface defined diligence questions, or support repeatable opportunity preparation within the agreed context.
Lonrú provides principal-led strategy, transaction framing, and review governance. Client scientific, clinical, manufacturing, legal, and commercial SMEs review work within their areas of accountability.
Reviewed outputs are delivered through a partner workspace, evidence view, valuation or scenario tool, market-intelligence interface, or other practical decision environment.
Connect the approved scientific, clinical, manufacturing, and commercial evidence behind the asset to the questions a prospective partner needs answered.
Create a clear view of the agreed clinical, manufacturing, market, and transaction assumptions that inform an out-licensing, co-development, or portfolio discussion.
Organise approved material, open questions, specialist input, and next actions so scientific teams and commercial leads can work from the same decision context.
Bring relevant therapeutic, competitor, and partner signals into a practical view that helps leadership focus the next engagement or evidence-building priority.
The architecture can prepare, structure, and test the evidence behind a partnering decision. It does not replace the scientific, legal, financial, or executive judgment required to approve a transaction.
We start with a defined objective and the approved sources needed to support it, keeping confidential material, decision rights, and external sharing boundaries explicit throughout the work.
Relevant experience
Under 8 weeks
Architected and deployed a custom, secure Advanced Therapy Partner Portal for a specialized clinical-stage provider in under 8 weeks, moving legacy spreadsheet-based partner tracking into an automated, role-governed deal-flow engine.
NPV modelling
Designed multi-dimensional pricing and Net Present Value modelling systems for cell and gene therapies, integrating clinical-trial milestones, manufacturing COG constraints, and quantified patient-benefit metrics.
Architecture in context
Diagram summary: Scientific, clinical, manufacturing, market, and transaction evidence is contextualised, analysed, and tested through ActiveArchitecture™ before it supports a partner or portfolio decision.
Practical questions
Next step
Bring the decision, workflow, or delivery constraint that needs a clearer operating path.
Request a focused briefing